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Despite a long history, Wilson’s disease, an autosomal recessive disease caused by mutations in the ATP7B gene,
remains a commonly misdiagnosed import disease. Mutations in ATP7B result in abnormal copper metabolism and
subsequent toxic accumulation of copper. Clinical manifestations of neurologic Wilson’s disease include variable
combinations of dysarthria, dystonia, tremor, and choreoathetosis. Among neurodegenerative diseases, it is unusual
in that misdiagnosis and delay in treatment are clinically relevant because treatments can prevent and cure Wilson’s
disease, if they are given appropriately. If left untreated, Wilson’s disease progresses to hepatic failure or severe
neurologic disability and death, while those adequately treated have normal life spans. This review focuses on the
neurologic features of Wilson’s disease, its diagnosis, and treatment options.
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The history of neurologic Wilson’s disease
The landmark paper in this disease was written
in 1912 by Samuel Alexander Kinnier-Wilson, an
American neurologist working at The National Hos-
pital at Queen Square in London.1 He described
a neurologic disorder associated with progressive
lenticular degeneration of the brain and cirrhosis
of the liver that came later to be known as Wilson’s
disease, or hepatolenticular degeneration. Prior to
Wilson’s description, Kayser in 1902 had described
pigmented corneal rings, later to bear his name,
in a patient believed affected by Wilson’s disease.
Wilson did not initially believe the connection of
Kayser-Fleischer rings or liver pathology to the dis-
ease that bears his name. The disease described by
Wilson was one dominated by juvenile age at onset
with dystonia and contrasts to the form of disease
described by Westpahl in 1883 as pseudosclerotic,
having a young-adult age of onset and symptomati-
cally consisting principally of tremor and dysarthria.
Only later was parkinsonism recognized as a major
clinical feature of Wilson’s disease.
A connection to copper metabolism may have
first been described in 1913 and was strengthened
by observations of sunflower cataracts in Wilson’s
disease. This type of cataract had been recognized as
being produced by copper-containing foreign bod-
ies. Subsequently, in 1929 and 1930 excess brain and
liver copper was described.2 In 1952 ceruloplasmin
was demonstrated to be low in Wilson’s patients.3
From 1963 through the mid 1970s use of radiocop-
per tracing by Walshe and colleagues demonstrated
that in presymptomatic disease the liver is able to
sequester injected copper. In symptomatic patients,
injected copper was unable to be bound in the liver
and was found in other tissues including the brain.4,5
A low biliary excretion of copper was later shown to
be responsible for a failure to regulate copper bal-
ance. An autosomal inheritance pattern was delin-
eated by Hall in 1921 and was confirmed by Bearn in
1960.6 The molecular era of medicine brought the
chromosomal localization of the Wilson’s disease
gene to chromosome 13q14.3 and identification of
the causative gene, ATP7B a copper transporting
P-type transmembrane ATPase.7–9
Cumings, who was the first to postulate an etio-
logic role for copper, suggested that chelation ther-
apy with British antilewisite (BAL or dimercaprol)
might be of benefit.10 The agent had been used dur-
ing World War II as an agent to treat lewisite, an
arsenic poison. By 1951, Cumings, Denny-Brown,
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and Porter described benefits of BAL in treatment
of Wilson’s disease.11,12 Alleviation of the painful
BAL injections and their associated toxicity became
possible with the description by Walshe in 1956 of
the potential use of penicillamine to chelate cop-
per in Wilson’s disease.13 Early in the 1960s use of
zinc as a decoppering agent was first undertaken
by Schouwink and Hoogenrand, findings that have
subsequently been borne out by larger trials.14,15
Seeking an alternate to penicillamine therapy, in
1969 Walshe began using trientine and has subse-
quently reported its beneficial effects in those re-
fractory to penicillamine.16 As had been observed
with zinc, molybdenum was know to induce cop-
per deficiency in sheep. This observation eventually
lead Walshe, in 1986, to consider its use in Wil-
son’s disease. The effectiveness of tetrathiomolyb-
date as a treatment of Wilson’s disease has now been
confirmed.17–20
Epidemiology
Wilson’s disease appears to be typical of rare auto-
somal recessive diseases in that it is present at a low
frequency in all populations. An estimate for the dis-
ease frequency in most populations is about 17 per
million, which would lead to a carrier frequency of 1
in 122.21 As with most autosomal recessive diseases,
there may be pockets of excess Wilson’s disease pro-
duced by founder effects, particularly if consanguity
is common in the population.22
Clinical manifestations
During early life, the patient is presymptomatic
but is accumulating copper, which invariably causes
subclinical liver disease. Then, between early child-
hood and the fifth or sixth decade of life, but with
a peak incidence of around 17 years, the patient
presents with hepatic, neurologic, and psychiatric
manifestations.23 It has been suggested that the hep-
atic, neurologic, and psychiatric presentations of
Wilson’s disease occur in roughly equal proportions.
An accurate estimate of the presenting proportions
is challenging because many of the large case se-
ries have ascertainment bias based on clinical spe-
cialty, and likely underrepresent the psychiatric pre-
sentation. Those with a primarily hepatic presen-
tation appear to have an earlier age at presentation
than those with the primarily neurologic presenta-
tion.23,24 Although Wilson’s disease usually presents
in childhood into early adulthood, a wider range of
age at onset is recognized. Generally, is extremely
rare for Wilson’s disease to present after age 35, but
late-onset cases continued to be reported.25 This re-
view deals primarily with neurologic Wilson’s dis-
ease, and hepatic manifestations will be briefly con-
sidered. Excellent descriptions of hepatic Wilson’s
disease can be found elsewhere.22,23,26
Neurologic manifestations
Neurologic subtypes
Walshe, who introduced penicillamine, trientine,
and tetrathiomolybdate therapy, stated that “no
two patients are ever the same, even in a sib-
ship,” and that there is no such thing as a typi-
cal picture of Wilson’s disease.27 Mean age at on-
set of neurologic symptoms from large case series
range from about 15–21 years of age.24,27–33 Neu-
rologic manifestations at initial presentation have
been reported in approximately 18–68%.27,29–31,34
The main clinical categories of neurologic Wil-
son’s disease have been variably divided by neu-
rologic presentation and signs. The clinical cate-
gories that encompass the majority of neurologic
Wilson’s disease are, dysarthric, dystonic, tremor,
pseudosclerotic (tremor +/– dysartrria), or parkin-
sonian.24,27–33,35–37 It is not uncommon for a single
manifestation such as tremor, dysarthria, dystonia,
or less frequently parkinsonism to be present at the
initiation of the symptomatic period. As the disease
progresses, it is typical for complex combinations
of neurologic symptoms and signs to coexist in a
single patient, with a small subset of features pre-
dominating. During the course of the disease, other
neurologic features include, chorea, athetosis, my-
oclonus, seizures, ataxia, pyramidal signs, drooling,
and eye movement abnormalities.27
Neurologic features
Dysarthria
Dysarthria is probably the most common neuro-
logic manifestation of Wilson’s disease. In large se-
ries that delineate dysarthria as a feature of Wil-
son’s disease, it has been found in 85–97% of those
with neurologic Wilson’s disease.29,31,37 Dysarthria
in Wilson’s disease is most frequently of the mixed
type with varying spastic, ataxic, hypokinetic, and
dystonic components.30,31,38 Speech involvement is
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frequently concordant with the neurologic involve-
ment in individual patients. In those with dystonia,
speech frequently will have dystonic qualities with a
strained or harsh quality. In those with parkinson-
ism, the speech quality may have hypokinetic prop-
erties.39 Ataxic dysarthria, with variation in word
spacing and volume, is often found in association
with other types of dysarthria and may be more
common in those with tremor.31
Dystonia
Dystonia can be focal, segmental, multifocal, or gen-
eralized and ranges in severity from mild to de-
bilitating.38 Dystonia is a common finding in Wil-
son’s disease, reported to be present in about 11–
65%.29–31,33,34,38 A common focal dystonic mani-
festation of Wilson’s disease is the dystonic facial
expression known as risus sardonicus. This type of
dystonia inflicts the patient with a forced, often ex-
aggerated, smile.38 Focal dystonia of the vocal cords,
muscle of articulation, and swallowing frequently
results in dysphonia, dysarthria, and dysphagia. Fo-
cal dystonia of the vocal cords, muscle of articula-
tion, and swallowing can be an initial isolated fea-
ture or part of a generalized dystonia. Other focal
dystonias include blepharospasm, cervical dystonia
(torticollis), and writer’s cramp. As the disease pro-
gresses focal dystonia can progress to segmental,
multifocal, hemidystonia, and generalized dystonia.
Dystonia, like many neurologic features of Wilson’s
disease, typically has a unilateral onset or predom-
inance, but can progress to bilateral or generalized
involvement. Severe dystonia may lead to extreme
posturing of the trunk, neck, or extremities. As in
other forms of dystonia, sensory tricks can often
lead to temporary improvement. The presence of
dystonia has been demonstrated to correlate with
MRI signal abnormalities in the putamen.31,38
Tremor
Wilsonian tremor has been reported to be present
in 22–55% and can occur at rest, upon assump-
tion of a posture, or with action.27,29,30,32,34 Al-
though widely known, the wing-beating tremor of
Wilson’s disease does not appear to be the most
frequent tremor type. Early in the neurologic pre-
sentation of Wilson’s disease, the tremor can be
identical to the tremor of essential tremor, with
the arms most frequently involved but also involv-
ing the head and legs. Persistence of tremor asym-
metry and absence of voice tremor may differen-
tiate this type of Wilsonian tremor from essential
tremor, which is typically symmetric and frequently
involves the voice. As the disease progresses, Wilso-
nian tremor may take on characteristics atypical of
essential tremor. It is not uncommon to encounter a
tremor with multiple position- and task-dependent
characteristics in an individual patient.32 The kinetic
tremor is most frequently a distal upper extremity,
low amplitude, medium-to-high frequency tremor.
The classical posture-induced wing-beating tremor,
thought to be associated with lesions of the denta-
dorubrothalamic pathway, is a less frequently ob-
served, lower frequency higher amplitude proximal
upper extremity tremor elicited by holding the arms
extended laterally or with the arms held in front
with flexed elbows and palms facing downward. The
wing-beating tremor is typified by increasing ampli-
tude with increased duration of posture holding.2 A
unilateral isolated rest tremor is atypical in Wilson’s
disease. When rest tremor is present it is usually ac-
companied by postural and kinetic tremor, which
may be more severe than the rest tremor.29
Parkinsonism
In series in which parkinsonism has been consid-
ered as a separate symptom category, it has been
reported in 19–62%.27,31,33,34 Bradykinesia, imbal-
ance, and cogwheel rigidity are the more common
parkinsonian features. Unilateral rest tremor and
parkinsonism are rarely isolated clinical feature of
Wilson’s disease, but like idiopathic Parkinson’s dis-
ease, rigidity, and tremor are typically asymmetric.
Choreoathetosis
Chorea and athetosis have been reported to occur
in 6–16% of those with neurologic Wilson’s dis-
ease.29–31,33,34,37 Chorea is characterized by invol-
untary irregular rapid movements of the face, head,
trunk, and extremities that are superimposed on
and interrupt normal movement. Choreic move-
ments can be subtle and small, occurring distally
in the fingers resembling piano playing movements,
and may also resemble fidgetiness and be incor-
porated into apparently purposeful movements. In
an extreme form, they can manifest as disabling
uncontrolled flailing movements of the extremities,
termed ballism. Chorea is frequently accompanied
by athetosis, a slow writhing movement of the limbs,
trunk, or neck, and this combination is referred to as
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choreoathetosis. When present in Wilson’s disease,
chorea is more common in young onset disease
(16 years of age and younger), where it has been re-
ported in 20%. In contrast, chorea was reported in
only 3% of adult onset (17 years of age and older).27
Chorea can have many causes40 and is not usually
present in isolation in neurologic Wilson’s disease.
Ataxia
Ataxia has been reported as a common feature in
Wilson’s disease, present in around 30%,29,33 but it
has not been observed or reported in other large
case series.27,31,32,34 Cerebellar findings are rarely
clinically relevant and are not found in isolation;
on exam, frank limb ataxia is infrequent. Cerebel-
lar signs, other than extremity dysmetria, such as
overshoot dysmetria of the eyes and limbs, or ataxic
dysarthria can be found.31
Cognition
Cognitive impairment in Wilson’s disease can be
subtle, masked by affective involvement and rec-
ognized only in retrospect by the family or pa-
tient. When present, cognitive impairment falls
into two main, not mutually exclusive, categories,
a frontal lobe syndrome, or a subcortical demen-
tia.41,42 The frontal syndrome may manifest as im-
pulsivity, promiscuity, impaired social judgment,
apathy, decreased attention, executive dysfunction
with poor planning and decision making, and emo-
tional lability, at an extreme having pseudobulbar
features. The subcortical dementia is characterized
by slowness of thinking, memory loss, and execu-
tive dysfunction, without cortical signs of aphasia,
apraxia, or agnosia.41,42 Others have suggested that
cognitive involvement in Wilson’s disease may be
primarily related to psychiatric and motor manifes-
tations.43,44
Other neurologic features
Seizures are not an uncommon feature, occurring
in approximately 6% (exceeding the general popu-
lation frequency by 10-fold), are rarely the present-
ing feature, and have been associated with initia-
tion of chelating therapy.45 Hyperreflexia, unusual
stereotyped movements, and tics have also been
reported.29
Ophthalmologic manifestations
Copper deposits in the limbic region of the cornea
known a Kayser-Fleischer (KF) rings are seen in
nearly 100% of those with neurologic Wilson’s dis-
ease, Figure 1.23,33,46 In hepatic and presymptomatic
Wilson’s disease KF rings are present in about 50%.23
KF rings are often evident by unaided visual inspec-
tion, but slit-lamp evaluation should be performed
to verify their presence. KF rings are typically brown
to brownish-green in color and are usually more
prominent in the superior and inferior regions of
the cornea. KF rings are not exclusive to Wilson’s
disease and can uncommonly be found in other
obstructive liver disease.47 Sunflower cataracts are
seen less commonly than KF rings, present in about
17%.46 Sunflower cataracts do not impair vision,
cannot be seen with the unaided eye or with an
ophthalmoscope, and require slit-lamp evaluation
for detection. With treatment, KF rings and sun-
flower cataracts become less prominent and can dis-
appear.46 Other less common ophthalmologic find-
ings include slowing of saccades, impaired upgaze,
and strabismus. The absence of nystagmus in Wil-
son’s disease can also be diagnostically useful.46
Figure 1. KF rings with prominence at the upper and lower corneal pole in an individual with brown eyes (left panel).
Prominent full-circle KF rings in an individual with blue eyes (right panel).
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Initial neurologic features
Knowledge of the ways neurologic Wilson’s dis-
ease first manifests is critical to early diagnosis
and prompt initiation of treatment. Unfortunately,
Wilson’s disease is often misdiagnosed, and the
average time from symptom onset to diagnostic
treatment is long, about 12 months.27,29,31 Ini-
tial misdiagnosis in Wilson’s disease includes over
100 different entities.48 Highlighting the diagnostic
challenge, initial neurologic misdiagnosis was found
to span a spectrum from “no diagnosis,” to “neuro-
logical problem,” and included many common and
rare entities.48
Diagnostic delay appears clinically significant, as
treatment outcomes have been demonstrated to be
better in those with a short diagnostic delay.16 In pa-
tients who made a “very good” recovery, becoming
free of neurologic symptoms, 21/57 (37%) had ini-
tiated therapy in less than 1 month. When delay in
diagnosis increased to 1–6 months only 7/36 (19%)
were able to achieve a “good” outcome, defined as
minor disability.16 It has also been shown that a
delay in diagnosis increases the likelihood of a poor
response to treatment. Walshe and Yealland demon-
strated an increasing likelihood of a “poor” response
to treatment as delay in diagnosis increased. Poor
response was defined as being left with major dis-
ability. In those diagnosed in less than 1 month 12%
had a poor outcome, diagnosis in 1–6 months lead
to 21% with poor recovery, a diagnostic delay of
7–18 months led to 19% with poor outcome, while
a greater than 18-month delay resulted in 38% with
major disability.16
The true initial neurologic manifestations of Wil-
son’s disease are illusive, but symptoms and signs at
diagnosis have been reported in a number of large
case series (Table 1).27,29–31,34 In studies that cate-
gorize initial manifestations, dysarthria is the most
common (57.6%), followed by dystonia (42.4%),
abnormal gait (37.8%), tremor (36.2%), parkin-
sonism (17.3%), chorea or athetosis (15.3%), and
seizures (4.7%). Ataxia was described as a separate
category in only one study.29 In these studies, inves-
tigations did not use the same criteria to define signs,
studies did not use the same categorization, and
the proportion of the time symptoms were present
in isolation was not specified. Dysarthria, dystonia,
tremor, and parkinsonism can be sole initial disease
manifestations.
Psychiatric features
Psychiatric manifestations may be present as often
as 30–50% of the time prior to a diagnosis of Wil-
son’s disease.43,44 Because psychiatric symptoms are
often ill defined and attributed to other causes, di-
agnosis of Wilson’s disease is rarely made during
the period in which psychiatric symptoms are the
sole manifestation. This aspect of Wilson’s disease is
likely a factor in diagnostic and treatment delay. At
diagnosis, the most common psychiatric symptoms
Table 1. Initial clinical features of neurologic Wilson’s disease
Total or
35a(%) 30b 28c 31d 32c (%Average)
Number of patients 48 119 136 27 31 361
Age at onset (years) 19.6 16.2 20.9 21
Diagnostic delay (months) ∼12 12.8 ∼12
Dysarthria 46 91 39 15 97 (57.6)
Dystonia 38 69 29 11 65 (42.4)
Abnormal gait 24 75 10 42 (37.8)
Tremor 22 55 35 37 32 (36.2)
parknisonism 12 58e 21 19 (17.3)
Chorea or athetosis 6 30 10 (15.3)
seizures 6 4.2 4 (4.7)
Ataxia/cerebellar 28
afirst manifestations, bat time of diagnosis, c initial signs of neurologic presentation, d initial symptoms of neurologic
presentation, ebradykinesia.
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have been reported to be personality change, in-
congruous behavior, irritability, and depression.44
During the course of disease, in addition to per-
sistence of the presenting psychiatric symptoms,
other features that can develop include impulsivity,
dysinhibition, irritability, reckless behavior, anxi-
ety, substance abuse, catatonia, emotionality, and
mania.43,44,49 Depression has been estimated to oc-
cur in 20–30% of those affected by Wilson’s disease.
It has been suggested that depression in Wilson’s
disease may be reactive, but this does not account
for those presenting with depression. Psychotic fea-
tures do not appear to be a common manifestation
of Wilson’s disease.44,49 Psychiatric manifestations
of Wilson’s disease appear to be more common with
neurologic involvement and are uncommon in the
hepatic presentation.44,50
Hepatic features of Wilson’s disease
The hepatic presentation can be divided into four
main presentations, acute hepatitis, chronic active
hepatitis, cirrhosis, and acute fulminant hepatic fail-
ure.51 Other hepatic presentations include clinical
pictures indistinguishable from alcoholic liver dis-
ease and autoimmune hepatitis.26 A younger on-
set is seen in those whose symptoms are first hep-
atic: 11–15 years of age.22,24 Because separating
hepatitis, cirrhosis, or liver failure due to Wilson’s
disease from other etiologies is clinically challeng-
ing, screening for Wilson’s disease should be per-
formed in the appropriate clinical setting. Patients
who present with hepatic failure may have mild fail-
ure with jaundice, low blood albumin, and edema,
but not be in an acute, rapidly deteriorating, ful-
minant liver failure. Other patients may present
with acute fulminant hepatic failure with Coombs-
negative hemolytic anemia, coagulopathy, renal fail-
ure, and encephalopathy.52 Hemolysis is believed to
occur secondary to large copper release by acute
hepatic necrosis. The occurrence of hemolysis in
hepatic disease should always trigger a search for
Wilson’s disease because it is by far the most likely
diagnosis. Patients with a neurologic presentation
frequently have subclinical liver disease with a mild-
to-moderate cirrhosis. For those with further inter-
est, excellent reviews regarding hepatic features of
Wilson’s disease are available.24,26,53
In addition to the neurologic, psychiatric, and
hepatic features, patients with Wilson’s disease may
have a variety of other clinical manifestations.
These include abnormalities of renal tubular func-
tion, including Fanconi syndrome. Renal stones and
gallstones are not uncommon. Patients may have
osteoporosis or osteomalacia, or they may have
joint disorders such as arthritis or arthralgias. Fe-
male patients frequently have oligomenorrhea or
amenorrhea. Abnormalities of the heart include
interstitial fibrosis and myocarditis. Electrocardio-
graphic abnormalities and orthostatic hypertension
are not uncommon. Pancreatic disease, parathy-
roidism, and skin abnormalities may be present.23
Natural history
Neurologic Wilson’s disease most frequently be-
comes symptomatic in late childhood through early
adulthood with a mean age of onset between 15 and
21 years of age.27,29–33 It is unusual for Wilson’s dis-
ease to become symptomatic after age 55, but a small
number have neurologic onset over age 55 (Ref. 54,
personal observation). Like the variable combina-
tions of disease manifestations, the clinical course of
Wilson’s disease is highly variable. Although symp-
toms are typically gradual in their progression, sud-
den worsening, both with and without treatment,
occurs. Day-to-day fluctuations of symptom sever-
ity is observed. It has been suggested that those with
tremor-predominant symptoms may have a slower
course than those with the predominantly dystonic
form.37 Younger-onset patents are more likely to
have chorea and dystonia, and less likely to have
a tremor predominant manifestation, whereas as
those with an older onset tend to have tremor as
the predominant sign.27 Prior to the treatment era,
the medial survival following development of neu-
rologic symptoms was approximately 2–5 years, but
Wilson’s disease can progress slowly over more than
25 years.16,55 In the absence of treatment, neuro-
logic symptoms were progressive and resulted in a
severely dystonic akinetic mute state with relative
preservation of cognition; untreated Wilson’s dis-
ease was inevitably fatal.23 Experience and detailed
investigations convincingly demonstrate the bene-
fit of treatment, with chelation therapy normalizing
life expectancy.16–20,24,33
Neuropathology
Wilson described softening of the lenticular nu-
clei, but it is now realized that brain pathology can
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be widespread and include the thalamus, subthala-
mic nuclei, brainstem, and frontal cortex. Grossly,
the brain often demonstrates atrophy and increased
ventricular size. The putamen and caudate can be
brown and shrunken. Cavitation and cyst forma-
tion in the putamen, and frontal lobes is seen in
advanced disease. Spongy degeneration of the cere-
beral cortex and subcortical white matter, particu-
larly in the frontal lobes, occurs. Microscopic eval-
uation of affected areas demonstrates neuronal loss,
pigment- and lipid-containing macrophages, and
gliosis; Opalaski cells in the globus pallidus are a
distinctive feature.22,56
Molecular genetics and pathogenesis
The Wilson’s disease gene was mapped to chromo-
some 13q14.3, and the causative gene identified as
ATP7B.7–9 ATP7B is a 1411–amino acid, copper-
transporting, P-type transmembrane ATPase that is
highly expressed in the liver, kidney, and placenta.7
Humans, including Wilson’s disease patients, take
in about 1.0 mg of copper per day in their diet and
have a requirement for only about 0.75 mg. Thus,
the extra 0.25 mg must be eliminated. The nor-
mal mechanism for elimination of excess copper is
excretion in the bile for loss in the stool. Dietary
copper is absorbed in the stomach and duodenum
and transported via the portal vein to the liver, the
main organ controlling copper regulation. Copper
is absorbed into hepatocytes by copper transporter
1, then ATOX1, a copper-specific chaperone protein,
transports copper to ATP7B. The normal function
of ATP7B appears to be incorporation of copper into
ceruloplasmin and secretion of copper into bile. As
a result of the mutation in the ATP7B gene, the liver
is not capable of excreting excess copper into the
bile, and a positive copper balance, averaging about
0.25 mg/d, is established. Copper accumulates over
time, first in the liver and then in other parts of the
body, such as in the brain. The damage from exces-
sive copper appears to be oxidant in nature.23,53
Wilson’s disease is an autosomal recessive disease
that occurs when a patient carries mutations in both
copies of his/her ATP7B gene. Mutational analysis
has identified over 300 different mutations through-
out the ATP7B gene. A much smaller number of mu-
tations is seen in the majority of patients, and indi-
vidual mutations have been associated with different
ethnic populations. The H1069Q substitution is the
most common mutation in white populations repre-
senting approximately 40–60% of identified muta-
tions.57 The H1069Q is not prominent in Chinese or
Indian populations, in whom other mutations, in-
cluding R778G, occur at higher frequency.58,59 The
H1069Q mutation, particularly when homozygous,
has been associated with a later onset neurologic
disease.60,61 Other consistent genotype–phenotype
correlations have been elusive. Because of the large
number of disease-causing mutations, most patients
are compound heterozygotes (have two different
mutations). It is not know how the same mutation
is able to cause hepatic disease in some, but neu-
rologic in others. A combination of environmental,
genetic, and epigenetic factors is likely responsible.
Differential diagnosis
Neurologic Wilson’s disease must be distinguished
from other common and rare neurologic diseases.
Because Wilson’s disease is treatable, it should be
considered as a possible diagnosis in every young
person with a movement disorder. The more com-
mon neurologic disorders that can mimic Wil-
son’s disease include essential tremor, young-onset
Parkinson’s disease, and generalized dystonia. Rare
juvenile genetic extrapyramidal disorders including
Huntington disease, Hallervorden-Spatz disease, id-
iopathic torsion dystonia, chorea-acanthocytosis,
and benign familial chorea can at times mimic
Wilson’s disease. Neither chorea nor ataxia is typi-
cally found in isolation, and although Wilson’s dis-
ease can be considered, diagnostic consideration for
other causes of primarily choreic and ataxic diseases
should be undertaken. The psychiatric abnormali-
ties may be mistaken for a psychological abnormal-
ity, affective disorder, early schizophrenia, or drug
abuse. The presence of Kayser-Fleischer rings and
the coexistence of liver disease provide important
clues.
Diagnostic workup
The most common screening method for Wilson’s
disease is a blood ceruloplasmin determination,
although this is inadequate for either ruling in
or ruling out Wilson’s disease. The ceruloplasmin
value is usually low in Wilson’s disease, but in ap-
proximately 10% of patients it may be normal or
near normal. About 10% of heterozygous carri-
ers who will never have clinical problems will also
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demonstrate low ceruloplasmin values. The most
useful screening procedure is a 24-h urine copper
test.22,23 In symptomatic Wilson’s disease 24-h urine
copper is always elevated to a value greater than
100 g per 24 h (normal is 50 or less). The 24-h
urine sample must be collected in a container free
of trace elements. A laboratory capable of measur-
ing copper in low concentrations is required to do
the assay. If these difficulties can be overcome, this
test is quite reliable in screening for Wilson’s disease.
Another common screening procedure is a slit-
lamp examination for KF rings. Visual inspection is
not adequate. KF rings are invariably present in the
psychiatric and neurologic presentations; however,
they are present in only about 50% of patients who
present with liver disease. In a patient with classical
clinical disease, KF rings, and elevated urine cop-
per, the diagnosis can be made with certainty. If any
question remains, the gold standard for diagnosis is
a measure of quantitative copper in a percutaneous
liver biopsy. The hepatic copper value in untreated
Wilson’s disease is above 200 g/g dry weight of tis-
sue, with normal being 50 g/g or less. Carriers of
the Wilson’s disease gene may have mild elevations
of hepatic copper, but never to 200 g/g. It is im-
portant not to rely on the stain for copper, for if the
copper is still diffusely cytoplasmic, the copper stain
may be negative in the face of very great elevations
of hepatic copper. Radiocopper studies have been
suggested for the diagnosis of Wilson’s disease, but
their usefulness is questionable. While these tests are
abnormal in Wilson’s disease, they are also abnor-
mal in carriers of the disease and thus are fraught
with the risk of misdiagnosis.23
The gene for Wilson’s disease has been cloned,7–9
fostering hope for the development of a direct DNA
test. This approach is not practical because more
than 300 different mutations that may cause Wil-
son’s disease have been identified.53,57 However, if
a mutation is identified in a proband, then search
for this mutation in relatives can provide crucial
information for the identification of as yet asymp-
tomatic relatives and of heterozygotes, and provides
the opportunity for preventive therapy and genetic
counseling.
Central nervous system imaging can be helpful in
the diagnosis, Figure 2. MRI scans generally demon-
strate abnormalities in patients with neurologic or
psychiatric symptoms but are often normal in pa-
tients with only liver disease. In neurologically in-
volved patients, the most common findings are areas
of high T2 signal in the lentiform and caudate nu-
clei, thalamus, brain stem, and white matter.31,62,63
High signal T1 images, like those in portal-systemic
encephalopathy may also be observed.64 Dopamine
D2 receptor binding and regional cerebral glucose
metabolism are reduced in the striatum and have
been shown to return to almost normal levels after
penicillamine therapy.65
Treatment
Wilson’s disease is a condition that can be effec-
tively treated. Treatment can be divided into initial
therapy, maintenance therapy, and treatment of the
presymptomatic patient.23,26 Available pharmaco-
logic agents include penicillamine, trientine, zinc
acetate, and tetrathiomolybdate. The aim of treat-
ment is to reduce the amount of toxic free copper.
Free copper is toxic whereas copper bound to ceru-
loplasmin or metallothionein is not.
Although penicillamine demonstrated clear ther-
apeutic advantages over BAL, initial neurologic
worsening following initiation of penicillamine
therapy is a concern. In their retrospective study,
Brewer and colleagues found that the risk for neuro-
logic worsening was about 50% when penicillamine
was used as initial treatment of neurologic Wilson’s
disease and that 50% of those who deteriorated
never recovered to their prepenicillamine baseline.66
The majority of patients observed to have deterio-
rated did so within 4 weeks of beginning penicil-
lamine therapy. It has been suggested that mobi-
lization of large hepatic copper stores raises blood
free-copper levels leading to increased toxic copper
exposure to the brain and subsequent worsening.66
Others have investigated the efficacy and toxic-
ity of penicillamine treatment of neurologic Wil-
son’s disease.24,32,67 In a description of their expe-
rience Walshe and colleagues described outcomes
following treatment of neurologic Wilson’s dis-
ease with penicillamine. In this study if toxicity
developed while using penicillamine, therapy was
switched to trientine. In some patients in this se-
ries, trientine was used as first-line therapy, and
in a small number zinc, BAL, or tetrathiomolyb-
date was used following penicillamine.16 In all, 137
patients were followed, 57 (41%) became symp-
tom free, 36 (26%) were left with minor neuro-
logic deficit, 24 (18%) were left disabled, and 20
180 Ann. N.Y. Acad. Sci. 1184 (2010) 173–187 c© 2009 New York Academy of Sciences.
Lorincz Wilson’s disease
Figure 2. Progressive MRI changes as shown in sequential brain fluid–attenuated inversion-recovery (FLAIR) imag-
ing in an individual with untreated Wilson’s disease. Representative images are shown at the level of the superior
cerebellar peduncle (first column), the midbrain (second column from the left), the basal ganglion (third column from
the left), and at the level of the cerebral cortex (right-most column). Images in the top, middle, and bottom rows were
obtained in 2001, 2002, and 2004, respectively.
(15%) died.16 Most patients who improved began
to do so in 3–6 months. Thirty (22%) had increased
symptom severity after initiation of treatment. In
those who had initial worsening, 11 (37% of those
who worsened) eventually became symptom free,
9 (30%) were left with minor neurologic deficit,
and 10 (33%) were left disabled.16 No features were
identified that were able to predict those who wors-
ened. Of individuals who died despite treatment,
no factors could be identified to predict who would
die. These patients were not more likely to present
with a dystonic phenotype, but most had became
severely dystonic prior to death.16 In this study
penicillamine was associated with toxicity requir-
ing discontinuation of its use in around 20%.16 In
another study of largely neurologic Wilson’s dis-
ease 44% discontinued penicillamine secondary to
side effects.68 Complications of penicillamine in-
clude rash, immune complex nephropathy, sys-
temic lupus erythematosus, thrombocytopenia, and
leucocytopenia.16,68
This study is additionally notable because neuro-
logic features were examined for an association with
treatment outcome. The pseudosclerotic (tremor
and dysarthric) form of neurologic Wilson’s disease
was found to be associated with the best chance of a
favorable outcome.16 Patients with the pseudoscle-
rotic form of neurologic Wilson’s disease were found
to have an 82% chance of becoming symptom free or
having minor neurologic deficit. Those with chorea
had a 75% chance, those with parkinsonism a 63%
chance, and those with dystonia a 53% chance of be-
coming symptom free or having minor neurologic
deficit.16
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Stremmel and colleagues described their expe-
rience with penicillamine in a total of 51 pa-
tients, 31 with neurologic Wilson’s disease.32 In
this study neurologic and hepatic Wilson’s were of-
ten considered together. Improvement in neurologic
features was described following penicillamine ther-
apy. No description of initial neurologic worsen-
ing was reported, but penicillamine-induced ad-
verse reactions occurred in 25%.32 Stremmel and
colleagues further described treatment of Wilson’s
disease in 163 additional Wilson’s disease patients,
58 with neurologic Wilson’s disease.24 In the neuro-
logic group, 54% improved, 22% were stable, and
24% worsened. Of all the patients 70.3% developed
side effects to penicillamine and 31% experienced
severe side effects including neurologic worsening.
Neurologic worsening occurred early after initiation
of therapy and in some did not improve.24
Because of concern for neurologic worsening in
those treated with penicillamine, use of other agents
has been recommended for initial treatment of neu-
rologic Wilson’s disease.14,20,24,69 If penicillamine is
used, the standard starting dose is 250 mg four times
a day or 500 mg twice a day. It has been suggested
that starting with lower doses, 250–500 mg per day
for a few weeks may lessen side effects.26 When ini-
tiated, the patient should be carefully monitored for
toxicities including to the bone marrow and kid-
ney. An acute hypersensitivity reaction occurs in
about 25% of patients, which may respond to cor-
ticosteroid therapy or withdrawal of the drug and
readministration in very low doses.
Trientine has often been used as an alternative
or second-line therapy, but like penicillamine it
can cause neurologic worsening in approximately
25%.20,26 Trientine is a chelator that, like penicil-
lamine, promotes urinary excretion of copper. Tri-
entine is used in doses of 750–1500 mg for initial
therapy and 750 mg to 1000 mg for maintenance
therapy, divided into two or three doses per day. It
should be given 1 h before or 2 h after meals. Al-
though trientine has fewer side effects than penicil-
lamine it shares a common mechanism of action and
can cause neurologic worsening. In a double-blind
study comparing tetrathiomolybdate to trientine,
24% of those treated with trientine experienced neu-
rologic worsening and in those who initially wors-
ened 50% died.20 While on trientine, urine copper
is a reflection of enhanced urinary copper excretion
and total body copper load. Upon initial treatment
with trientine, 24-h urinary copper excretion may
be 1000–3000 g (normal is 20–50 g/24 h). Af-
ter a few weeks urinary copper decreases to 500–
1000 g per 24 h, and after approximately 1 year of
therapy it should decrease to 200–500 g per 24 h.
Nonceruloplasmin-bound copper, free copper, is a
useful measure for monitoring efficacy of trientine
and can be calculated by the formula: (Total serum
copper in g/mL × 100) – (ceruloplasmin in mg/dL
× 3) = free copper (normal range is 5–15 g/dL).
Another way that free copper can be accurately es-
timated is by subtracting 3 g for every 1 mg/dL of
ceruloplasmin from the serum copper, expressed as
g/dL. During the maintenance phase of trientine
therapy keeping free copper below 25 mg is the goal.
Zinc acetate therapy has been used successfully
as a preventative therapy in presymptomatic pa-
tients, as initial treatment for neurologic Wilson’s
disease, and as maintenance therapy following an
initial course of decoppering.69,70 Zinc induces in-
testinal cell metallothionein, a protein that com-
plexes intestinal food copper or endogenously se-
creted copper in saliva and gastric secretions. The
complex cannot be absorbed in to the blood, and
as intestinal cells die they, along with the complex,
are sloughed into the stool resulting in a negative
copper balance. The net effect of zinc therapy is
an intestinal blockade of zinc absorption. Zinc has
the additional effect of inducing hepatocyte metal-
lothionein production, which may reduce the toxic
effect of free copper in these cells.22,70
The decoppering effect of zinc is slow: a pe-
riod of 4–8 months of treatment is required to
reduce copper to nontoxic levels. In symptomatic
individuals, the natural course of disease contin-
ues during this period and can lead to permanent
worsening. To avoid potential toxicities of trientine
and penicillamine, some have successfully used zinc
in the initial treatment of neurologic Wilson’s dis-
ease.15,69,71–75 An advantage of zinc is its lack of se-
rious significant side effects and safety in long-term
use.71,76 Approximately 10% experience gastric dis-
comfort or nausea upon initiation of zinc therapy.
The use of the zinc acetate compared to zinc sul-
fate reduces gastric discomfort. Generally, gastric
symptoms subside within days to weeks. For main-
tenance and prophylactic therapy in adults, 50 mg
of zinc three times a day is recommended.69,70,76
It is important to separate the zinc from food by
at least an hour. For maintenance therapy zinc is
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favored over penicillamine or trientine, because
while all three drugs are effective, zinc has a su-
perior side-effect profile and does not appear to
cause neurologic worsening.23,69 Because zinc ther-
apy does not induce urinary excretion of copper, as
do trientine or penicillamine, urine copper is an ac-
curate reflection of body copper stores. Following a
year of zinc therapy, a 24-h copper of around 125 g
is a reflection of good copper control. Compliance
with zinc can be assessed by monitoring 24-h urine
zinc excretion, which should be above 2 mg.22
For the initial treatment of patients presenting
with neurologic or psychiatric disease, the use of
tetrathiomolybdate (TM) followed by zinc mainte-
nance therapy has been suggested to provide a good
best balance of efficacy and side effects, but TM is
not yet FDA approved.20 TM acts by forming a tri-
partite complex with copper and protein. Given with
food, TM binds food copper and endogenously se-
creted copper preventing copper absorption. Given
between meals, TM is absorbed into the blood and
forms a complex with free copper and albumin.
Free copper in the blood is in equilibrium with
tissue copper so that binding of serum copper to
TM shifts the equilibrium to mobilize copper from
tissue stores into serum where it is bound by TM
and excreted into bile. The result is a rapid removal
of tissue copper, which is then bound in the serum
by TM, reducing potential copper toxicity, and sig-
nificantly less neurologic worsening compared to
penicillamine or trientine.17–20 In a double-blind
study 48 patients were randomized to TM or trien-
tine for the initial treatment of neurologic Wilson’s
disease. TM, 20 mg three times a day with meals and
20 mg three times a day between meals, or trientine,
500 mg two times per day, were given for 8 weeks
with zinc, 50 mg twice daily, followed by zinc main-
tenance therapy. Both trientine and TM were found
to improve neurologic and speech function, but TM
was significantly less likely to be associated with neu-
rologic worsening than trientine.20 In the trientine
arm 6 of 23 (26%) patients worsened neurologically,
and 3 of those who worsened died. In the TM arm
1 of 25 (4%) patients developed neurologic dete-
rioration, a statistically significant difference. In an
earlier open-label study of TM in initial treatment of
neurologic Wilson’s disease 2 of 55 (3.6%) patients
treated with TM worsened.19 Serious adverse effects
from TM were not observed. TM was associated
with reversible increases in transaminase levels and
anemia in about 15%.19,20 Anemia and transami-
nase elevations responded to temporary suspension
of TM without subsequent abnormalities following
reinitiation of TM at half dose.19,20 24-h urine cop-
per monitoring during treatment with TM can be
used to monitor therapy. In untreated Wilson’s dis-
ease, 24-h urinary excretion always exceeds 100 g
per 24 h. The goal of treatment following an initial
course of TM followed by maintenance therapy with
zinc is a 24 h urine copper excretion of 50–100 g. A
study evaluating lower doses of TM is ongoing (G.J.
Brewer, personal communication, 2008). It is an-
ticipated that TM will be FDA approved, and more
widely available.
Some have reported that individuals with decom-
pensated liver disease treated with orthotopic liver
transplant demonstrated improvement of neuro-
logic symptoms.77,78 Other studies have not demon-
strated a benefit, and orthotopic liver transplant
is not recommended as a treatment for neurologic
Wilson’s disease.22,79 In those studies reporting on
the effect of treatment, the largest degree of im-
provement was observed between 6 months and
2 years of adequate copper control, with some ben-
efit reported to occur for up to 3 years.20,24,32,43,44,67
The response to treatment is variable. Few studies
have systematically investigated or reported the ef-
fect of treatment on individual neurologic signs or
symptoms. Currently no reliable predictors exist to
differentiate those who will make an excellent re-
covery from those whose symptoms will stabilize
but not improve. It has been suggested that tremor
may be more treatment responsive than dystonia
and dysarthria.16,36 Those who did not respond to
treatment tended to have a more severe neurologic
disease, with more frequent dysarthria and dysto-
nia.16,44 In those severely impaired by neurologic
Wilson’s disease, attempts to determine factors as-
sociated with a good recovery were not found.67
Symptomatic treatment of the movement disor-
ders found in Wilson’s patients has not be carefully
studied, and response to treatment is inconsistent.16
There are no good studies that have investigated
dopamine agonists for treatment of parkinsonism
in Wilson’s disease. L-dopa and dopamine agonists
do not appear to provide reliable relief of parkinson-
ism. -blockers and primidone, medications used to
treat essential tremor, can be tried in those with lim-
iting essential tremor-like tremor, but their benefit is
limited. Artane, baclofen, and valium can be used in
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symptomatic therapy of dystonia. Speech and phys-
ical therapy can provide a great deal of benefit.
Psychiatric manifestations of Wilson’s disease also
have a variable response to treatment. Incongruous
behavior and cognitive impairment were reported to
be more treatment responsive than irritability or de-
pression. Improvements tended to occur relatively
early in the course of treatment, before 3.5 years,
and then reach a plateau.44 Others have suggested
that the most prominent improvement occurs be-
tween 6 and 18 months following initiation of ther-
apy and then plateaus after 2 years of copper-level
normalization.43
In patients who present with liver disease, if the
disease if fulminant, hepatic transplant may be the
only way to save the patient’s life. However, in cases
of mild hepatic failure, a picture of chronic cirrho-
sis, or a picture of mild hepatitis, medical treatment
can be quite effective. The prognostic index of Nazer
is useful in differentiating which patients will likely
do well with medical therapy.80 The combination of
trientine followed by zinc maintenance may repre-
sent the best medical treatment for hepatic Wilson’s
disease. The trientine is given to obtain a rather ro-
bust negative copper balance. Zinc is given to induce
hepatic metallothionein and allow that metalloth-
ionein to complex copper in the liver in a nontoxic
form. This combination is used for 4 months and
then the trientine is discontinued.
Over the years, considerable attention has been
paid to diet in Wilson’s disease. In the United States
only liver and shellfish are high enough in copper
to be of concern.22,23 Because animals are fed high
levels of minerals, the liver can be very high in copper
and should not be ingested during the decoppering
period (first 4 months) and after that only in small
amounts. Shellfish are intermediately high in copper
and should not be ingested during the decoppering
period and not ingested more often than once a week
during maintenance therapy. Other foods are not
restricted because the content of copper is not high
enough to be of concern. Occasionally, drinking-
water samples will be found to be high in copper. If
the level is higher than about 0.1 ppm the patient
should use an alternative source of drinking water.
Prevention
Identification and treatment of presymptomatic
Wilson’s disease patients can prevent development
of symptoms. Aggressive screening measures in
clinic populations at risk are critical. An important
target population is the siblings of the newly diag-
nosed patient. Each sibling has a 25% risk of being in
the presymptomatic disease stage. Because prophy-
lactic therapy will prevent the onset of the disease,
these patients should be examined and disease sta-
tus determined. All full siblings should be screened
for blood ceruloplasmin, and 24-h urine copper lev-
els. A 24-h urine copper in presymptomatic siblings
with a value of 100 is diagnostic of Wilson’s disease.
If it is less than 50 in an adult patient, it essentially
excludes the diagnosis. If it is intermediate, it is com-
patible either with the carrier state, since some of
these patients have mild elevations of urine copper,
or the presymptomatic affected state, since some
of these patients do not have diagnostic levels of
urine copper. The patients in this intermediate zone
should have a liver biopsy to make the diagnosis.
The liver copper level in such a patient is diagnostic.
Because the risk of Wilson’s disease is significantly
elevated in nieces and nephews (1/600) and cousins
(1/800), compared to the general population, these
relatives can be screened for ceruloplasmin and 24-h
urine copper levels.
Conclusion
The history of Wilson’s disease is remarkable in
many aspects. Like other well known neurodegen-
erative diseases such as Alzheimer’s or Parkinson’s
disease, pioneering individuals contributed seminal
observations regarding disease features and etiology.
Unlike other neurodegenerative diseases this work
has lead to treatment that can essentially cure the
disease. Unfortunately, neurologic Wilson’s disease
continues to suffer from clinically significant diag-
nostic delay. Currently available therapies have had a
major positive impact on the outcome of neurologic
Wilson’s disease, but have limitations. Future stud-
ies promise to delineate optimal therapeutic regimes
and improved clinical outcomes.
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